News & Updates

Compared with dipeptidyl peptidase-4 inhibitors (DPP4i), the use of sodium glucose co-transporter 2 inhibitors (SGLT2i) is associated with lower risk of cardiovascular disease, renal events, and heart failure (HF) hospitalization among patients with diabetes, reports a recent study.

Undergoing a hysterectomy, particularly at a young age, may be associated with an increased risk of developing diabetes, according to a study from France presented at EASD 2022.

In the context of an energy-restricted diet, a weight-loss diet involving daily consumption of 70 g of lightly salted dry-roasted peanuts yielded similar weight loss results as a traditional low-fat weight-loss diet after 6 months in adults at high risk for type 2 diabetes (T2D), a study has shown.

A 2-week comprehensive risk-management regimen can successfully suppress levels of plasma triglycerides in patients with type 2 diabetes (T2D), a recent study reported.

Updated results of the SUGAR* trial showed that using polymer-free amphilimus-eluting stents (AES) was not a superior option to durable-polymer zotarolimus-eluting stents (ZES) in patients with diabetes mellitus who required percutaneous coronary intervention (PCI).

Vitamin C appears to protect against metabolic disorders due to its close association with glucose-lipid metabolism in overweight and obese patients who are undergoing laparoscopic sleeve gastrectomy (LSG), according to a study. Moreover, LSG does not seem to worsen the vitamin C status or deficiency.

A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).

Combination therapy with metformin plus R-form verapamil (R-Vera) leads to significant improvements in glycaemic control by reducing haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients with type 2 diabetes (T2D), reports a study.